CoChat
Sign Up
Cited by 38Advanced Glycation End Products researchAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer's disease

Open access
Wang, Michelle Y., Ross-Cisneros, Fred N., Aggarwal, Divya, Liang, Chiao-Ying, Sadun, Alfredo A.·2009·Acta Neuropathologica
DOI 10.1007/s00401-009-0513-4PMC PMC2867613
Open this paper in CoChat — free account

Abstract

Although Alzheimer's disease (AD) has been shown to be associated with a true primary optic neuropathy, the underlying pathophysiology of this disease and in particular the optic nerve disorder is still poorly understood. The receptor for advanced glycation end products (RAGE) has been implicated in the pathogenesis of AD by mediating the transport of plasma amyloid-beta into the brain. Once ligated, RAGE can play a role in signal transduction, leading to amplification and perpetuation of inflammatory processes. As a key player in the reaction to CNS injury, astrocytes have been shown to associate with RAGE in a number of diseases, including AD. To investigate the role of RAGE and astrocytes in the pathogenesis of AD optic neuropathy, we conducted immunohistochemical studies to examine the presence of RAGE in donor eyes from patients with AD (n = 10) and controls (n = 3). Both qualitative observation and quantitative analyses using imaging software were used to document the extent of RAGE in the neural tissues. The intensity and extent of RAGE expression was more prominent in AD nerves compared to controls (P < 0.05). The RAGE immunoreactivity was observed in the microvasculature and in close proximity to astrocytic processes. While RAGE immunoreactivity increased with age, the increase was more precipitous in the AD group compared to the controls. The up-regulation of RAGE in the AD optic nerves indicates that RAGE may play a role in the pathophysiology of AD optic neuropathy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-009-0513-4

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 36

  1. [1]Arancio O Zhang HP Chen X 2004 RAGE potentiates abeta-induced perturbation of neuronal function in transgenic mice EMBO J 23 4096 4105 10.1038/sj.emboj.7600415 15457210 PMC524347 · DOI
  2. [2]Bierhaus A Humpert PM Morcos M 2005 Understanding RAGE, the receptor for advanced glycation end products J Mol Med 83 876 886 10.1007/s00109-005-0688-7 16133426 · DOI · Paper page
  3. [3]Braak H Alafuzoff I Arzberger T Kretzschmar H Del Tredici K 2006 Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry Acta Neuropathol 112 389 404 10.1007/s00401-006-0127-z 16906426 PMC3906709 · DOI · Paper page
  4. [4]Brett J Schmidt AM Yan SD 1993 Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues Am J Pathol 143 1699 1712 8256857 PMC1887265
  5. [6]Deane R Du Yan S Submamaryan RK 2003 RAGE mediates amyloid-beta peptide transport across the blood–brain barrier and accumulation in brain Nat Med 9 907 913 10.1038/nm890 12808450 · DOI · Paper page
  6. [7]Donahue JE Flaherty SL Johanson CE 2006 RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease Acta Neuropathol 112 405 415 10.1007/s00401-006-0115-3 16865397 · DOI · Paper page
  7. [8]Dickson DW Farlo J Davies P Crystal H Fuld P Yen SH 1988 Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques Am J Pathol 132 86 101 2456021 PMC1880629
  8. [9]Duffy PE Rapport M Graf L 1980 Glial fibrillary acidic protein and Alzheimer-type senile dementia Neurology 30 778 782 7190246
  9. [10]Emanuele E D'Angelo A Tomaino C 2005 Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia Arch Neurol 62 1734 1736 10.1001/archneur.62.11.1734 16286548 · DOI
  10. [11]Frosch MP Anthony DC de Girolami U 2005 The central nervous system Kumar V Abbas AK Fausto N Robbins and Cotran pathologic basis of disease 7th Elsevier Saunders Philadelphia 1347 1420
  11. [12]Griffin WS Stanley LC Ling C 1989 Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease Proc Natl Acad Sci USA 86 7611 7615 10.1073/pnas.86.19.7611 2529544 PMC298116 · DOI · Paper page
  12. [13]Hebert LE Scherr PA Bienias JL Bennett DA Evans DA 2003 Alzheimer disease in the US population: prevalence estimates using the 2000 census Arch Neurol 60 1119 1122 10.1001/archneur.60.8.1119 12925369 · DOI · Paper page
  13. [14]Hinton DR Sadun AA Blanks JC Miller CA 1986 Optic-nerve degeneration in Alzheimer's disease N Engl J Med 315 485 487 3736630
  14. [15]Hyman BT Trojanowski JQ 1997 Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease J Neuropathol Exp Neurol 56 1095 1097 10.1097/00005072-199710000-00002 9329452 · DOI · Paper page
  15. [16]Katz B Rimmer S 1989 Ophthalmologic manifestations of Alzheimer's disease Surv Ophthalmol 34 31 43 10.1016/0039-6257(89)90127-6 2678551 · DOI
  16. [17]Li JJ Dickson D Hof PR Vlassara H 1998 Receptors for advanced glycosylation endproducts in human brain: role in brain homeostasis Mol Med 4 46 60 9513189 PMC2230261
  17. [18]Ma L Nicholson LF 2004 Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus Brain Res 1018 10 17 10.1016/j.brainres.2004.05.052 15262199 · DOI
  18. [19]Mackic JB Stins M McComb JG 1998 Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1–40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer J Clin Invest 102 734 743 10.1172/JCI2029 9710442 PMC508936 · DOI · Paper page
  19. [20]Mandybur TI Chuirazzi CC 1990 Astrocytes and the plaques of Alzheimer's disease Neurology 40 635 639 1690867
  20. [21]Miller MC Tavares R Johanson CE 2008 Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease Brain Res 1230 273 280 10.1016/j.brainres.2008.06.124 18657529 PMC2585053 · DOI · Paper page
  21. [22]Mirra SS Heyman A McKeel D 1991 The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease Neurology 41 479 486 2011243
  22. [23]Mruthinti S Buccafusco JJ Hill WD 2004 Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides Neurobiol Aging 25 1023 1032 10.1016/j.neurobiolaging.2003.11.001 15212827 · DOI
  23. [24]Onyango IG Tuttle JB Bennett JP Jr 2005 Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE) Mol Cell Neurosci 29 333 343 10.1016/j.mcn.2005.02.012 15911356 · DOI
  24. [25]Pichiule P Chavez JC Schmidt AM Vannucci SJ 2007 Hypoxia-inducible factor-1 mediates neuronal expression of the receptor for advanced glycation end products following hypoxia/ischemia J Biol Chem 282 36330 36340 10.1074/jbc.M706407200 17942394 · DOI
  25. [26]Pike CJ Cummings BJ Monzavi R Cotman CW 1994 Beta-amyloid-induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer's disease Neuroscience 63 517 531 10.1016/0306-4522(94)90547-9 7891862 · DOI
  26. [27]Ramasamy R Vannucci SJ Yan SS Herold K Yan SF Schmidt AM 2005 Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation Glycobiology 15 16R 28R 10.1093/glycob/cwi053 15764591 · DOI · Paper page
  27. [28]Sadun AA 1989 The optic neuropathy of Alzheimer's disease Metab Pediatr Syst Ophthalmol 12 64 68 2770524
  28. [29]Sadun AA Borchert M DeVita E Hinton DR Bassi CJ 1987 Assessment of visual impairment in patients with Alzheimer's disease Am J Ophthalmol 104 113 120 3618708
  29. [30]Sadun AA Bassi CJ 1990 Optic nerve damage in Alzheimer's disease Ophthalmology 97 9 17 2314849
  30. [32]Schmidt AM Yan SD Yan SF Stern DM 2000 The biology of the receptor for advanced glycation end products and its ligands Biochim Biophys Acta 1498 99 111 10.1016/S0167-4889(00)00087-2 11108954 · DOI
  31. [33]Schmidt AM Yan SD Yan SF Stern DM 2001 The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses J Clin Invest 108 949 955 11581294 PMC200958
  32. [34]Stern D Yan SD Yan SF Schmidt AM 2002 Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings Adv Drug Deliv Rev 54 1615 1625 10.1016/S0169-409X(02)00160-6 12453678 · DOI
  33. [35]Wyss-Coray T Loike JD Brionne TC 2003 Adult mouse astrocytes degrade amyloid-beta in vitro and in situ Nat Med 9 453 457 10.1038/nm838 12612547 · DOI · Paper page
  34. [36]Yan SD Chen X Fu J 1996 RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease Nature 382 685 691 10.1038/382685a0 8751438 · DOI · Paper page
  35. [37]Zlokovic BV 2004 Clearing amyloid through the blood–brain barrier J Neurochem 89 807 811 10.1111/j.1471-4159.2004.02385.x 15140180 · DOI · Paper page
  36. [38]Zlokovic BV 2005 Neurovascular mechanisms of Alzheimer's neurodegeneration Trends Neurosci 28 202 208 10.1016/j.tins.2005.02.001 15808355 · DOI

Cited by

Sorted by citations

Authors
Wang, M. Y., Ross-Cisneros, F. N., Aggarwal, D., Liang, C.-Y., & Sadun, A. A.
Affiliations
University of Southern California (US)
Corresponding author
Sadun, Alfredo A.
ORCID
Venue
Acta Neuropathologica
Publisher
Springer Science and Business Media LLC
Published
2009-03-11
Volume
118
Issue
3
Pages
381-389
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
DOI
10.1007/s00401-009-0513-4
PMC
PMC2867613
OpenAlex
W2021841801
Cited by
38
References
2
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 1 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 5 · 2014: 1 · 2013: 5 · 2012: 2
FWCI
1.49
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Acta Neuropathologica (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Research to Prevent Blindness
  • National Eye Institute (P30EY003040, #EY03040, R01EY011396)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, optic neuropathy, receptor for advanced glycation end products, RAGE, astrocytes, optic nerve, amyloid-beta transport, neuroinflammation, microcirculation
MeSH terms
Receptor for Advanced Glycation End Products, Age Factors, Aged, Aged, 80 and over, Alzheimer Disease, Astrocytes, Female, Humans, Immunohistochemistry, Male, Middle Aged, Optic Nerve, Optic Nerve Diseases, Receptors, Immunologic, Up-Regulation, Microvessels

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review